Cause or consequence in idiopathic pulmonary fibrosis: using genetic data to back the right horse

Louise V Wain
DOI: https://doi.org/10.1136/thorax-2024-222011
2024-08-19
Thorax
Abstract:The task is clear: we need better treatments for pulmonary fibrosis (PF). The two antifibrotic therapies licensed for idiopathic pulmonary fibrosis (IPF) have shown efficacy in other forms of PF but do not meet the needs of people living with PF; drugs that can halt or even reverse progression and, importantly, improve quality of life. Although a number of new potential therapies are now reaching late-stage clinical trials, the recent failure of three of these has been disheartening1 and highlights the need to dig deeper, and smarter, for new potential drug targets. Over the last 9 years, several studies have shown that drug targets with support from genetic association studies were more likely to be successful in clinical development than those without.2–4 This has prompted considerable interest and investment in the generation of genetic data by academia and industry. The supposition...
respiratory system
What problem does this paper attempt to address?